The association of smoking with preclinical cognitive decline remains unclear and may be modified by the APOEɛ4 genotype. In 5,705 participants (mean age: 63.9±9.1 years; 57.4% women) from the population-based Rotterdam Study, we investigated the relationship between smoking and cognitive decline over a 5.5-year period and examined potential effect modification by APOEɛ4 genotype. We found that current smoking was related to decline in global cognition [difference compared to never smoking: –0.06 (95% C.I.–0.10;–0.01)], as well as decline on specific cognitive tests including the Letter Digit Substitution Task, the 15-Word Learning Test, and the Purdue Pegboard. We found no evidence for effect modification by APOEɛ4 genotype on this relation.
OttA, SlooterAJC, HofmanA, Van HarskampF, WittemanJCM, Van BroeckhovenC, Van DuijnCM, BretelerMMB (1998) Smoking and risk of dementia and Alzheimer’s disease in a population-based cohort study: The Rotterdam Study. Lancet351, 1840–1843.
2.
AnsteyKJ, von SandenC, SalimA, O’KearneyR (2007) Smoking as a risk factor for dementia and cognitive decline: A meta-analysis of prospective studies. Am J Epidemiol166, 367–378.
3.
WhitmerRA, SidneyS, SelbyJ, JohnstonSC, YaffeK (2005) Midlife cardiovascular risk factors and risk of dementia in late life. Neurology64, 277–281.
4.
ReitzC, den HeijerT, van DuijnC, HofmanA, BretelerM (2007) Relation between smoking and risk of dementia and Alzheimer disease. Neurology69, 998–1005.
5.
DurazzoTC, MattssonN, WeinerMW (2016) Interaction of cigarette smoking history with APOE genotype and age on amyloid level, glucose metabolism, and neurocognition in cognitively normal elders. Nicotine Tob Res18, 204–211.
6.
WangR, FratiglioniL, LaukkaEJ, LövdénM, KellerL, GraffC (2015) Effects of vascular risk factors and APOE e 4 on white matter integrity and cognitive decline. Neurology84, 1128–1135.
7.
LahozC, SchaeferEJ, CupplesLAA, WilsonPWF, LevyD, OsgoodD, ParposS, Pedro-BotetJ, DalyJA, OrdovasJM (2001) Apolipoprotein E genotype and cardiovascular disease in the Framingham Heart Study. Atherosclerosis154, 529–537.
8.
WilsonPWF, SchaeferEJ, LarsonMG, OrdovasJM (1996) Apolipoprotein E alleles and risk of coronary disease. Arterioscler Thromb Vasc Biol16, 1250–1255.
9.
FabrigouleC, RouchI, TaberlyA, LetenneurL, CommengesD, MazauxJM, OrgogozoJM, DartiguesJF (1998) Cognitive process in preclinical phase of dementia. Brain121, 135–141.
10.
JacobsDM, SanoM, DooneiefG, MarderK, BellKL, SternY (1995) Neuropsychological detection and characterization of preclinical Alzheimer’s disease. Neurology45, 957–962.
11.
HofmanA, BrusselleGGO, MuradSD, van DuijnCM, FrancoOH, GoedegebureA, IkramMA, KlaverCCW, NijstenTEC, PeetersRP, StrickerBHC, TiemeierHW, UitterlindenAG, VernooijMW (2015) The Rotterdam Study: 2016 objectives and design update. Eur J Epidemiol30, 661–708.
12.
HeeringaJ, KorsJA, HofmanA, van RooijFJA, WittemanJCM (2008) Cigarette smoking and risk of atrial fibrillation: The Rotterdam Study. Am Heart J156, 1163–1169.
13.
HoogendamYY, HofmanA, Van Der GeestJN, Van Der LugtA, IkramMA (2014) Patterns of cognitive function in aging: The Rotterdam Study. Eur J Epidemiol29, 133–140.
14.
PinskyPF, MillerA, KramerBS, ChurchT, RedingD, ProrokP, GelmannE, SchoenRE, BuysS, HayesRB, BergCD (2007) Evidence of a healthy volunteer effect in the prostate, lung, colorectal, and ovarian cancer screening trial. Am J Epidemiol165, 874–881.
AbergA, BergstrandR, JohanssonS, UlvenstamG, VedinA, WedelH, WilhelmssonC, WilhelmsenL (1983) Cessation of smoking after myocardial infarction. Effects on mortality after 10 years. Br Heart J49, 416–422.
17.
CritchleyJA, CapewellDS (2003) Mortality risk reduction associated with smoking cessation in patients with coronary heart disease a systematic review. J Am Med Assoc290, 86–97.
